The scientific team
at Amira is responsible for an impressive portfolio of compounds,
including AM103, an oral,
next generation inhibitor of 5-lipoxygenase-activating protein
(FLAP).
Within two years of the company's founding in 2005,
Amira’s drug
hunters discovered four highly-targeted, novel compounds. |
